6185.HK Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Mai 2024 @ 08:34):

Stats
Tagesvolumen	584 000
Durchschnittsvolumen	1.11M
Marktkapitalisierung	6.97B
EPS	HKD-0.580 ( 2023-10-30 )
Last Dividend	HKD0.937 ( 2022-07-13 )
Next Dividend	HKD0 ( N/A )
P/E	-3.31
ATR14	HKD0.0180 (0.08%)

Volumen Korrelation

Lang: -0.15 (neutral)

Kurz: 0.22 (neutral)

Signal:(66.565) Neutral

Cansino Biologics Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Cansino Biologics Inc Korrelation - Währung/Rohstoff

0.31
( neutral )

0.35
( neutral )

0.00
( neutral )

0.37
( neutral )

-0.33
( neutral )

Cansino Biologics Inc Finanzdaten

Annual	2023
Umsatz:	HKD345.18M
Bruttogewinn:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2023
Umsatz:	HKD345.18M
Bruttogewinn:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2022
Umsatz:	HKD1.03B
Bruttogewinn:	HKD-186.61M (-18.10 %)
EPS:	HKD-3.91

FY	2021
Umsatz:	HKD4.30B
Bruttogewinn:	HKD3.00B (69.85 %)
EPS:	HKD7.74

Financial Reports:

No articles found.

Cansino Biologics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.937 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Cansino Biologics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.937	2022-07-13
Last Dividend	HKD0.937	2022-07-13
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	HKD0.937	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-03)

HKD0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
1270.HK	Ex Dividend Knight	2023-05-16	Annually	0.00%
0322.HK	Ex Dividend Junior	2023-06-07	Annually	0.00%
6069.HK	Ex Dividend Junior	2023-06-28	Annually	0.00%
1821.HK	Ex Dividend Junior	2023-09-07	Semi-Annually	0.00%
0856.HK	Ex Dividend Junior	2023-05-31	Annually	0.00%
0006.HK	Ex Dividend Knight	2023-08-30	Semi-Annually	0.00%
2607.HK	Ex Dividend Junior	2023-07-18	Annually	0.00%
1397.HK	Ex Dividend Junior	2023-06-21	Sporadic	0.00%
0458.HK	Ex Dividend Junior	2023-09-07	Sporadic	0.00%
6836.HK	Ex Dividend Junior	2023-07-07	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-4.24	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.159	1.200	-5.30	-6.36	[0 - 0.3]
returnOnEquityTTM	-0.252	1.500	-3.91	-5.86	[0.1 - 1]
payoutRatioTTM	-0.0725	-1.000	-0.725	0.725	[0 - 1]
currentRatioTTM	1.999	0.800	5.01	4.00	[1 - 3]
quickRatioTTM	1.835	0.800	3.91	3.13	[0.8 - 2.5]
cashRatioTTM	0.790	1.500	6.72	10.00	[0.2 - 2]
debtRatioTTM	0.290	-1.500	5.17	-7.76	[0 - 0.6]
interestCoverageTTM	-37.09	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-3.62	2.00	-1.207	-2.41	[0 - 30]
freeCashFlowPerShareTTM	-6.10	2.00	-3.05	-6.10	[0 - 20]
debtEquityRatioTTM	0.512	-1.500	7.95	-10.00	[0 - 2.5]
grossProfitMarginTTM	-1.411	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-3.70	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.330	1.000	-2.95	-2.95	[0.2 - 2]
assetTurnoverTTM	0.0376	0.800	-3.08	-2.47	[0.5 - 2]
Total Score				-3.45

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.98	1.000	-0.402	0	[1 - 100]
returnOnEquityTTM	-0.252	2.50	-2.51	-5.86	[0.1 - 1.5]
freeCashFlowPerShareTTM	-6.10	2.00	-2.03	-6.10	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-3.62	2.00	-1.207	-2.41	[0 - 30]
payoutRatioTTM	-0.0725	1.500	-0.725	0.725	[0 - 1]
pegRatioTTM	0.173	1.500	-2.18	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-2.55	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.75

Cansino Biologics Inc

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.